Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and Brain
Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced initiation of a Phase 1 open label clinical trial to establish the safety of
Checkpoint Surgical Receives FDA Breakthrough Designation for Nerve Regeneration Device
Checkpoint Surgical, a leader in hand-held, intraoperative neurostimulation technology for nerve protection and repair, announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Checkpoint brief electrostimulation therapy (BEST) system. The Checkpoint BEST™